Diagnostic testing in people with primary ciliary dyskinesia: An international participatory study

Diagnostic tests are important in primary ciliary dyskinesia (PCD), a rare disease, to confirm the diagnosis and characterize the disease. We compared diagnostic tests for PCD between countries worldwide, assessed whether people with PCD recall their tests, and identified factors associated with the use of tests. We used cross-sectional data from COVID-PCD--an international participatory cohort study collecting information directly from people with PCD. The baseline questionnaire inquired about tests used for PCD diagnosis. Using logistic regression, we investigated factors associated with measurement of nasal nitric oxide (nNO), biopsy for electron or video microscopy, and genetic testing. We included data from 747 participants (60% females) from 49 countries worldwide with median age 27 (interquartile range 12-44). Most (92%) reported diagnostic tests for PCD. Participants reported measurements of nNO (342; 49%), biopsy samples (561; 75%), and genetic tests (435; 58%). The reported use of individual tests, such as genetics, varied between countries from 38% in Switzerland to 68% in North America. Participant recall of test type also differed between countries with lowest recall in Switzerland. One-third (232; 36%) of participants reported all three tests (nNO, biopsy, and genetics). Recently diagnosed people reported more tests [nNO odds ratio (OR) 2.2, 95% Confidence Interval (CI) 1.5-3.2; biopsy OR 3.2, 95%CI 2.1-4.9; genetics OR 4.7, 95%CI 3.2-6.9] and those with situs abnormalities fewer tests (nNO OR 0.5, 95%CI 0.4-0.7; biopsy OR 0.5, 95%CI 0.4-0.8; genetics OR 0.7, 95%CI 0.5-0.94). Our results indicate PCD diagnostic testing differed widely around the world and many patients received incomplete diagnostic work-up based only on clinical features or single tests. People diagnosed long ago and those with situs abnormalities possibly benefit from supplementary testing to refine their diagnosis as a prerequisite for personalized medicine.

[1]  M. Carroll,et al.  Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis , 2022, European Respiratory Journal.

[2]  R. Truty,et al.  The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis. , 2022, The Lancet. Respiratory medicine.

[3]  C. Serra‐Juhé,et al.  Current Status of Genetic Counselling for Rare Diseases in Spain , 2021, Diagnostics.

[4]  I. Dokal.  Faculty Opinions recommendation of 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[5]  N. S. Thomas,et al.  Whole genome sequencing in the diagnosis of primary ciliary dyskinesia , 2021, BMC Medical Genomics.

[6]  H. Omran,et al.  Current and Future Treatments in Primary Ciliary Dyskinesia , 2021, International journal of molecular sciences.

[7]  M. Goutaki,et al.  Phenotype–genotype associations in primary ciliary dyskinesia: where do we stand? , 2021, European Respiratory Journal.

[8]  T. Ferkol,et al.  Emerging Genotype-Phenotype Relationships in Primary Ciliary Dyskinesia , 2021, International journal of molecular sciences.

[9]  Julie M. Robillard,et al.  Access to genetic testing for rare diseases: Existing gaps in public‐facing information , 2021, World medical & health policy.

[10]  G. Carlsson,et al.  Topological data analysis reveals genotype–phenotype relationships in primary ciliary dyskinesia , 2021, European Respiratory Journal.

[11]  C. Kuehni,et al.  COVID-PCD a participatory research study on the impact of COVID-19 in people with Primary Ciliary Dyskinesia , 2020, medRxiv.

[12]  H. Omran,et al.  Primary ciliary dyskinesia in the genomics age. , 2020, The Lancet. Respiratory medicine.

[13]  M. De Santis,et al.  Patient empowerment of people living with rare diseases. Its contribution to sustainable and resilient healthcare systems. , 2019, Annali dell'Istituto superiore di sanita.

[14]  P. Yiallouros,et al.  Time trends in diagnostic testing for primary ciliary dyskinesia in Europe , 2019, European Respiratory Journal.

[15]  M. Rosenfeld,et al.  Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[16]  H. Omran,et al.  European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia , 2017, European Respiratory Journal.

[17]  C. Kuehni,et al.  Toward an Earlier Diagnosis of Primary Ciliary Dyskinesia. Which Patients Should Undergo Detailed Diagnostic Testing? , 2016, Annals of the American Thoracic Society.

[18]  L. Behan,et al.  Diagnosing primary ciliary dyskinesia: an international patient perspective , 2016, European Respiratory Journal.

[19]  C. Kuehni,et al.  Clinical manifestations in primary ciliary dyskinesia: systematic review and meta-analysis , 2016, European Respiratory Journal.

[20]  P. Lackie,et al.  Accuracy of diagnostic testing in primary ciliary dyskinesia , 2015, European Respiratory Journal.

[21]  M. Rosenfeld,et al.  Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline , 2018, American Journal of Respiratory and Critical Care Medicine.

[22]  M. Rosenfeld,et al.  Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. , 2015, American journal of respiratory and critical care medicine.

[23]  T. Kenny,et al.  Overcoming challenges in the management of primary ciliary dyskinesia: the UK model. , 2014, Paediatric respiratory reviews.

[24]  M. Strippoli,et al.  Management of primary ciliary dyskinesia in European children: recommendations and clinical practice , 2012, European Respiratory Journal.

[25]  M. Strippoli,et al.  Factors influencing age at diagnosis of primary ciliary dyskinesia in European children , 2010, European Respiratory Journal.

[26]  H Omran,et al.  Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children , 2009, European Respiratory Journal.

[27]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[28]  A. Aylsworth.  Clinical aspects of defects in the determination of laterality. , 2001, American journal of medical genetics.

[29]  A. Brand,et al.  Personalized Medicine: What's in it for Rare Diseases? , 2017, Advances in experimental medicine and biology.